Regulus advances to cohort 3 of Phase 1b trial of ADPKD trial

Regulus announced will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD, after review of all available safety data. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months. The company prepares to share top line data from the second cohort in 1Q24. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult patients with ADPKD. The study will evaluate RGLS8429 treatment across three different dose levels. No safety issues were identified in cohort 2 based on the review of all available blinded safety data allowing advancement to cohort 3.